Company intelligence / Profile preview
BioVascular
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and planned trials for peripheral artery grafts in early 2007. A second product targeting cardiovascular risk factors was planned to enter human studies in mid 2007.
- Therapeutic areas
- NephrologyCardiovascular
- Modalities
- Recombinant proteinSmall moleculeDevice
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merck KGaA
Beyond the preview
Go deeper on BioVascular.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioVascular.